The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPersimmon Regulatory News (PSN)

Share Price Information for Persimmon (PSN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,366.50
Bid: 1,360.50
Ask: 1,361.50
Change: 61.00 (4.67%)
Spread: 1.00 (0.074%)
Open: 1,318.50
High: 1,366.50
Low: 1,309.50
Prev. Close: 1,305.50
PSN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

16 Apr 2014 07:00

RNS Number : 9142E
Persimmon PLC
16 April 2014
 



INTERIM MANAGEMENT STATEMENT

 

WEDNESDAY 16 APRIL 2014

 

 

Persimmon plc ("the Company") will hold its Annual General Meeting ("AGM") at 12.00 noon today at York Racecourse when the Chairman will make the following statement regarding current trading, financial performance and the outlook for the current financial year. This statement covers the period from 1 January 2014 to date and supplements the update given with the 2013 Final Results on 25 February 2014.

 

The new financial year has started well with visitor levels to our sites up 10% over the prior year during the initial fifteen weeks of trading. Cancellation rates over this period of 14% continue to run at historically low levels (2013: 15%).

 

Our weekly private sales rate per site for the first fifteen weeks of 2014 was 25% ahead of the prior year. Together with the strong sales position brought forward into the new year, this improved rate of sale results in current total forward sales of £1.87 billion for 2014, which includes legal completions taken so far this year. Total forward sales revenue is 35% higher than in 2013 (£1.38 billion). We have c.7,200 new homes sold forward into the private sale market for 2014 which is 38% ahead of the same point last year, with an average selling price of c.£200,400 which is c.3% higher.

 

We currently have c.395 active sites across the UK and have successfully opened 75 of the 90 new outlets targeted for the first half of 2014 to refresh this network. Our build activity continues to support the improved rates of sale and we remain confident of delivering further growth in the number of new homes legally completed for 2014.

 

The Government sponsored Help to Buy shared equity scheme in England reached its first anniversary on 1 April 2014 and we have now sold c.5,000 new homes to customers using mortgages associated with this scheme, of which 2,203 legally completed in 2013. In addition, we have sold a further c.600 new homes in Scotland and Wales to customers using similar mortgage products in these regional markets.

 

The recently announced extension of Help to Buy from March 2016 to March 2020 provides welcome support to potential new home purchasers for this additional four year period. As a consequence, and with the support of the mortgage lending industry, housebuilders have the opportunity to continue to increase the industry's development commitments in support of increasing the number of new homes delivered to the market over the medium term.

 

Our strategy remains focussed on exercising capital discipline through the cycle whilst growing the business as market conditions allow. Our commitment to return c.£1.9 billion of surplus capital to shareholders over the period to 2021 is a key feature of this capital discipline. In the Final Results statement on 25 February 2014 the Directors announced a further acceleration of this programme of capital return. Subject to shareholder approval at the AGM, the second payment of the Capital Return Plan of c.£213 million, or 70p per share, will be paid to shareholders on 4 July 2014. This 70p per share payment is a part acceleration of the 115p final payment originally planned for 2021. The record date is 6.00 p.m. on 4 June 2014 and the shares trade ex-entitlement from 8.00 a.m. on 5 June 2014.

 

In line with the approach adopted with the first payment under the Capital Return Plan in 2013, the Directors will offer shareholders the opportunity, where possible, to choose to receive the cash either as a return of capital or as dividend income by way of a B / C share scheme. Full details of the B / C share proposal have been sent to shareholders with the notice of the Company's AGM. The closing date for elections to be made by shareholders is 11.00 a.m. on 20 June 2014.

 

The Directors are pleased to announce that the Company has recently concluded an amendment of its £300 million Revolving Credit Facility with the Company's five relationship banks. The new facility has been extended to a maturity date of 31 March 2019.

 

We will provide a further report on progress in our Trading Update on Wednesday 2 July 2014.

 

For further information please contact:-

 

Jeff Fairburn, Group Chief Executive

Simon Rigby

Mike Killoran, Group Finance Director

Kevin Smith

Persimmon plc

Lindsay Noton

Tel: +44 (0) 20 7638 9571 on the day

Citigate Dewe Rogerson

Tel: +44 (0) 1904 642199 thereafter

Tel: +44 (0) 20 7638 9571

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUVANRSKASAAR
Date   Source Headline
1st May 20241:11 pmRNSTotal Voting Rights
30th Apr 20242:03 pmRNSDirectorate Change
25th Apr 20242:09 pmRNSResult of AGM
25th Apr 20247:00 amRNSQ1 Trading Statement
2nd Apr 20241:49 pmRNSTotal Voting Rights
28th Mar 202412:53 pmRNSDirector/PDMR Shareholding
25th Mar 20244:47 pmRNSDirector/PDMR Shareholding
25th Mar 20242:07 pmRNSAnnual Report 2023 and Notice of AGM 2024
12th Mar 20241:38 pmRNSDirector/PDMR Shareholding
12th Mar 20247:00 amRNSFull Year Results
11th Jan 20246:00 pmRNSDechra Pharmaceuticals
10th Jan 20247:00 amRNSTrading Statement
1st Dec 20234:48 pmRNSBlock listing Interim Review
1st Dec 20234:45 pmRNSTotal Voting Rights
17th Nov 202310:25 amRNSHolding(s) in Company
8th Nov 20237:00 amRNSAppointment of Chief Financial Officer
7th Nov 20237:00 amRNSQ3 Trading Statement
3rd Nov 20231:15 pmRNSHolding(s) in Company
1st Sep 20231:15 pmRNSTotal Voting Rights
10th Aug 20237:04 amRNSHalf Year Results
27th Jul 202310:13 amRNSDirectorate Change
10th Jul 20239:27 amRNSDirector Declaration
3rd Jul 20232:46 pmRNSTotal Voting Rights
1st Jun 20234:38 pmRNSTR-1: Notification of major holdings
1st Jun 20231:07 pmRNSBlock listing Interim Review
1st Jun 202311:06 amRNSTotal Voting Rights
3rd May 20235:00 pmRNSHolding(s) in Company
3rd May 20234:12 pmRNSDirector/PDMR Shareholding
2nd May 202311:13 amRNSTotal Voting Rights
26th Apr 20234:32 pmRNSResult of AGM
26th Apr 20237:00 amRNSQ1 Trading Statement
3rd Apr 20234:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20233:05 pmRNSTotal Voting Rights
27th Mar 20233:44 pmRNSDirector/PDMR Shareholding
22nd Mar 20233:00 pmRNSAnnual Report 2022 and Notice of AGM 2023
13th Mar 20231:57 pmRNSDirectorate Change
13th Mar 202312:19 pmRNSUK Government Self Remediation Contract Signed
7th Mar 20235:33 pmRNSHolding(s) in Company
7th Mar 20237:04 amRNSDirector Declaration
6th Mar 20235:02 pmRNSHolding(s) in Company
1st Mar 20237:00 amRNSFull Year Results
12th Jan 20237:00 amRNSTrading Statement
1st Dec 20225:30 pmRNSBLOCK LISTING SIX MONTHLY RETURN
1st Dec 20225:25 pmRNSVoting Rights and Capital
8th Nov 20227:00 amRNSTrading Statement
1st Nov 20221:00 pmRNSTotal Voting Rights
1st Nov 20229:24 amRNSHolding(s) in Company
10th Oct 20222:24 pmRNSDirector/PDMR Shareholding
5th Oct 202210:26 amRNSHolding(s) in Company
4th Oct 20223:07 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.